Advertisement

Topics

Despite Promising Early Data, The New Cholesterol Lowering Drug - PCSK9si - Has Significant Hurdles

03:45 EDT 19 Oct 2016 | Forbes

If efficacy and safety are similar, it’s the price that matters most.

Original Article: Despite Promising Early Data, The New Cholesterol Lowering Drug - PCSK9si - Has Significant Hurdles

NEXT ARTICLE

More From BioPortfolio on "Despite Promising Early Data, The New Cholesterol Lowering Drug - PCSK9si - Has Significant Hurdles"

Quick Search
Advertisement